Clinical Trials Logo

Advanced Solid Tumors Cancer clinical trials

View clinical trials related to Advanced Solid Tumors Cancer.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04196283 Completed - Clinical trials for Advanced Solid Tumors Cancer

A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Start date: January 22, 2020
Phase: Phase 1
Study type: Interventional

The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

NCT ID: NCT03311477 Completed - Clinical trials for Advanced Solid Tumors Cancer

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

Start date: November 6, 2017
Phase: Phase 1
Study type: Interventional

An open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-399 in participants with advanced solid tumors.

NCT ID: NCT03234712 Completed - Clinical trials for Advanced Solid Tumors Cancer

A Study Evaluating the Safety, Pharmacokinetics, and Anti-tumor Activity of ABBV-321 in Subjects With Advanced Solid Tumors Associated With Overexpression of the Epidermal Growth Factor Receptor (EGFR)

Start date: October 10, 2017
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase 1, dose-escalation study to determine the maximum tolerated dose (MTD) and the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-321 for participants with advanced solid tumors likely to overexpress the epidermal growth factor receptor (EGFR). The study will consist of 2 phases: Dose Escalation Phase and Expansion Phase.

NCT ID: NCT03071757 Completed - Clinical trials for Advanced Solid Tumors Cancer

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Start date: March 21, 2017
Phase: Phase 1
Study type: Interventional

The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or metastatic solid tumors. The study will consist of 3 parts: ABBV-368 dose escalation, ABBV-368 tumor-specific dose expansion (triple negative breast cancer [TNBC] cohort and head and neck cancer cohort) and 18F-AraG Imaging Substudy.

NCT ID: NCT02955251 Completed - Clinical trials for Advanced Solid Tumors Cancer

A Study of ABBV-428, an Immunotherapy, in Subjects With Advanced Solid Tumors

Start date: November 18, 2016
Phase: Phase 1
Study type: Interventional

This is an open-label, Phase I, dose-escalation study to determine the recommended Phase 2 dose (RPTD), maximum tolerated dose (MTD), and evaluate the safety and pharmacokinetic (PK) profile of ABBV-428 when administered as monotherapy or in combination with nivolumab in participants with advanced solid tumors.